| General Information of Drug Metabolite (DM) (ID: DM019086) |
| DM Name |
TAK-272 Metabolite M1
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
TAK-272
|
[1] |
|
Cytochrome P450 3A5 (CYP3A5)
|
DME0012
|
| Unclear - Unclear |
TAK-272
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| TAK-272 |
DR3278
|
Phase 2 |
Type-2 diabetes |
|
|
| References |
| 1 |
Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
